Login / Signup

Addressing the Role of Angiogenesis in Patients with Advanced Pancreatic Neuroendocrine Tumors Treated with Everolimus: A Biological Prospective Analysis of Soluble Biomarkers and Clinical Outcomes.

Chiara Alessandra CellaFrancesca SpadaAlfredo BerrutiFrancesco BertoliniPatrizia MancusoMassimo BarberisEleonora PisaManila RubinoLorenzo GervasoAlice LaffiStefania PellicoriDavide RadiceLaura ZorzinoAngelica CalleriLuigi FunicelliGiuseppe PetraliaNicola Fazio
Published in: Cancers (2022)
Our study suggested the evidence that circulating cells might be surrogate biomarkers of angiogenesis activity in patients treated with everolimus and their baseline levels can be correlated with survival. However, further studies are now needed to validate the role of these cells as surrogate markers for the selection of patients to be candidates for antiangiogenic treatments.
Keyphrases
  • induced apoptosis
  • neuroendocrine tumors
  • cell cycle arrest
  • end stage renal disease
  • newly diagnosed
  • endothelial cells
  • ejection fraction
  • chronic kidney disease
  • signaling pathway
  • peritoneal dialysis
  • wound healing